Lys138
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys138  -  RhoGDI alpha (human)

Site Information
HtyRKGVkIDkTDYM   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 31089519

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 1 ) , modification-specific antibody ( 1 ) , mutation of modification site ( 3 ) , western blotting ( 1 )
Disease tissue studied:
colorectal cancer ( 3 ) , colorectal carcinoma ( 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 ) , E.coli (bacterial) ( 1 ) , HCT116 (intestinal) ( 3 )

Downstream Regulation
Effects of modification on RhoGDI alpha:
phosphorylation ( 3 )
Effects of modification on biological processes:
carcinogenesis, inhibited ( 3 ) , cell cycle regulation ( 3 ) , cell growth, inhibited ( 3 ) , signaling pathway regulation ( 3 ) , transcription, inhibited ( 3 )

References 

1

Kuhlmann N, et al. (2016) Structural and Mechanistic Insights into the Regulation of the Fundamental Rho Regulator RhoGDI╬▒ by Lysine Acetylation. J Biol Chem 291, 5484-99
26719334   Curated Info

2

Impens F, Radoshevich L, Cossart P, Ribet D (2014) Mapping of SUMO sites and analysis of SUMOylation changes induced by external stimuli. Proc Natl Acad Sci U S A 111, 12432-7
25114211   Curated Info

3

Cao Z, et al. (2014) SUMOylation of RhoGDI╬▒ is required for its repression of cyclin D1 expression and anchorage-independent growth of cancer cells. Mol Oncol 8, 285-96
24342356   Curated Info